Molecule Name |
DB13179
|
DrugBank Groups |
Approved
|
Cluster No |
67
|
Smiles |
O=C2(OC(C(C(OC(=O)C)C(C(=O)C1(OC1)(CC(C(C(C(C2C)OC3(OC(C(OC(=O)C)C(C3)OC)C))C)OC4(OC(CC(C4OC(=O)C)N(C)C)C))C))C)C)C)
|
Download |
mol2, pdbqt
|
TPSA |
184,19
|
Non-H Atoms |
57
|
Non-C/H Atoms |
16
|
Metal-Atoms |
0
|
Electronegative Atoms |
16
|
Stereo Centers |
18
|
Rotatable Bonds |
12
|
Rings Closures |
4
|
Small Rings |
3
|
Aromatic Rings |
0
|
Aromatic Atoms |
0
|
sp3-Atoms |
47
|
Symmetric atoms |
1
|
cLogS |
-4,92
|
MW |
813,975
|
cLogP |
2,9271
|
HBA |
16
|
HBD |
0
|
Ro5 violations |
2
|
Druglikeness |
3,4781
|
DrugScore |
0,078056584127624
|
Mutagenic |
high
|
Tumorigenic |
high
|
Reproductive Effective |
none
|
Irritant |
high
|
Blood-Brain Barrier |
BBB-
|
Human Intestinal Absorption |
HIA+
|
Caco-2 Permeability |
Caco2-
|
P-glycoprotein Substrate |
Substrate
|
P-glycoprotein Inhibitor |
Inhibitor
|
P-glycoprotein Inhibitor 2 |
Non-inhibitor
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Aqueous solubility |
-2,7412
|
Caco-2 Permeability 2 |
1,2006
|
Subcellular localization |
Lysosome
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 2D6 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Substrate
|
CYP450 1A2 Inhibitor |
Non-inhibitor
|
CYP450 2C9 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 2C19 Inhibitor |
Non-inhibitor
|
CYP450 3A4 Inhibitor |
Inhibitor
|
CYP Inhibitory Promiscuity |
Low CYP Inhibitory Promiscuity
|
Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition 2 |
Non-inhibitor
|
AMES Toxicity |
AMES toxic
|
Carcinogens |
Non-carcinogens
|
Fish Toxicity |
High FHMT
|
Fish Toxicity (pLC50, mg/L) |
0,9724
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity (pIGC50, ug/L) |
0,4998
|
Honey Bee Toxicity |
High HBT
|
Biodegradation |
Not ready biodegradable
|
Acute Oral Toxicity |
IV
|
Rat Acute Toxicity (LD50, mol/kg) |
2,2177
|
Carcinogenicity (Three-class) |
Non-required
|